SCHEMBL23102243

SCHEMBL23102243

CC1CCN(S(=O)(=O)N2CCCN(CC3CCCCC3)CCCN(S(=O)(=O)c3ccc(N(C)C)cc3)CC3(CC3)C2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
TDP1 Q9NUW8 2/20 0.43
TSHR P16473 1/20 0.39
MAPT P10636 3/20 0.39
XBP1 P17861 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
NR3C1 P04150 1/20 0.37
LMNA P02545 3/20 0.37
ACHE P22303 1/20 0.37
ALDH1A1 P00352 3/20 0.36
GAA P10253 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23102233 0.94 TSHR (0.44) KMT2AMEN1TDP1TSHRMAPT
SCHEMBL23102163 0.94 TSHR (0.44) KMT2AMEN1TDP1TSHRMAPT
SCHEMBL21361559 0.94 TSHR (0.44) KMT2AMEN1TDP1TSHRMAPT
Hydrochloric Acid SCHEMBL21359222 0.94 TSHR (0.43) KMT2AMEN1TDP1TSHRMAPT
SCHEMBL23102111 0.92 HSD11B1 (0.39) KMT2AMEN1TDP1TSHRMAPT
SCHEMBL23102239 0.91 NPSR1 (0.44) KMT2AMEN1TSHRXBP1OPRM1
SCHEMBL23102166 0.91 TSHR (0.39) KMT2AMEN1TSHRMAPTXBP1
SCHEMBL23102121 0.91 HSD11B1 (0.41) KMT2AMEN1TSHRMAPTXBP1
SCHEMBL25388946 0.89 CYP3A4 (0.41) KMT2AMEN1TSHRXBP1OPRM1
SCHEMBL23102161 0.88 ALDH1A1 (0.43) KMT2AMEN1TSHRMAPTXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G KMT2A 4856/4885MEN1 2214/4885TDP1 3113/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KMT2A 4863/4885MEN1 2318/4885TDP1 2940/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KMT2A 4868/4885MEN1 2274/4885TDP1 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.